Skip to main content
. 2024 Jan 22;11:1342388. doi: 10.3389/fcvm.2024.1342388

Figure 4.

Figure 4

Effect of Totum-070 on intestinal lipid metabolism. (A) Total lipid content in feces (n = 5 per group). (B) Quantification of different lipid classes in feces. CE, cholesterol ester; CER, ceramides; DAG, diacylglycerides; DCER, dihydroceramides; FFA, free fatty acids; HCER, hexosylceramides; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; SM, sphingomyelin; and TG, triacylglycerides. (C,D) Relative expression of selected genes implicated in cholesterol and lipoprotein metabolism in jejunum (C), and ileum samples (D) (n = 14 samples per tissue and per group). (E) Quantification of different bile acid classes in feces (n = 5 per group). αMCA, α-muricholic acid; βMCA, β-muricholic acid; CA, cholic acid; UDCA, ursodeoxycholic acid; HDCA, hyodeoxycholic acid; DCA, deoxycholic acid. (F) Inhibition of lipase activity by Totum-070, n = 4–11 replicates. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 vs. ND. #p < 0.05, ##p < 0.01, ###p < 0.001 and ####p < 0.0001 Totum-070 (T070) groups vs. WD. Data are the mean ± SEM.